Insider Buying: Hologic, Inc. (NASDAQ:HOLX) Director Buys $300,781.80 in Stock

Hologic, Inc. (NASDAQ:HOLX) Director Martin D. Madaus bought 5,445 shares of the business’s stock in a transaction on Wednesday, May 7th. The shares were bought at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the acquisition, the director now directly owns 5,445 shares in the company, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Hologic Stock Performance

Shares of HOLX opened at $56.74 on Monday. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67. The company has a market cap of $12.73 billion, a PE ratio of 17.90, a P/E/G ratio of 2.14 and a beta of 0.54. The stock has a 50-day moving average of $59.43 and a 200-day moving average of $68.17. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.03 earnings per share. On average, equities research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on HOLX shares. Leerink Partnrs lowered Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Royal Bank of Canada dropped their price target on shares of Hologic from $75.00 to $70.00 and set a “sector perform” rating on the stock in a research report on Friday, May 2nd. Raymond James reaffirmed an “outperform” rating and issued a $71.00 price objective (down from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Evercore ISI lowered their target price on shares of Hologic from $65.00 to $62.00 and set an “in-line” rating for the company in a research note on Friday, May 2nd. Finally, William Blair reaffirmed an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Twelve analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $78.58.

Institutional Trading of Hologic

Several hedge funds have recently bought and sold shares of HOLX. Norges Bank bought a new position in shares of Hologic in the fourth quarter valued at $133,414,000. Victory Capital Management Inc. raised its holdings in shares of Hologic by 34.4% in the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider’s stock worth $408,283,000 after acquiring an additional 1,692,177 shares during the last quarter. Boston Partners lifted its position in Hologic by 81.0% in the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock valued at $257,959,000 after acquiring an additional 1,602,463 shares in the last quarter. Champlain Investment Partners LLC acquired a new position in Hologic during the 4th quarter valued at about $79,291,000. Finally, Redwood Wealth Management Group LLC bought a new stake in Hologic during the 1st quarter worth approximately $3,534,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.